Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol 2017;71:17–34.
Ploussard G, Fiard G, Barret E, Brureau L, Créhange G, Dariane C, et al. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. Prog Urol. 2022;32:1275–372.
Article CAS PubMed Google Scholar
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148–63.
Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol. 2020;203:734–42.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Article PubMed PubMed Central Google Scholar
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
Article PubMed PubMed Central Google Scholar
Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. Ann Math Stat. 1950;21:607–11.
Deeks JJ, Altman DG, Bradburn MJ. Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis. 2024; Available from: https://onlinelibrary.wiley.com/doi/10.1002/9780470693926.ch15.
Wang N. Conducting Meta-analyses of Proportions in R. J Behav Data Sci. 2023;3:64–126.
Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017;17:737–43.
Article CAS PubMed Google Scholar
Dickinson L, Ahmed HU, Hindley RG, McCartan N, Freeman A, Allen C, et al. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol. 2017;35:30.e9–30.e15.
Article CAS PubMed Google Scholar
von Hardenberg J, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, et al. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. Urol Oncol. 2018;36:401.e1–401.e9.
Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E, et al. Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed? Eur Radiol. 2018;28:3760–9.
Rosenhammer B, Niessen C, Rotzinger L, Reiss J, Schnabel MJ, Burger M, et al. Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer. Urol Int. 2019;103:270–8.
Article CAS PubMed Google Scholar
Bass R, Fleshner N, Finelli A, Barkin J, Zhang L. Klotz L. Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol. 2019;201:113–9.
Mortezavi A, Krauter J, Gu A, Sonderer J, Bruhin J, Reeve KA, et al. Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. J Urol. 2019;202:717–24.
Shoji S, Hiraiwa S, Uemura K, Nitta M, Hasegawa M, Kawamura Y, et al. Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of oncological and functional outcomes. Int J Clin Oncol. 2020;25:1844–53.
Article CAS PubMed Google Scholar
Bacchetta F, Martins M, Regusci S, Jichlinski P, Meuwly JY, Lucca I, et al. The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer. Urol Oncol. 2020;38:846.e1–846.e7.
Rompré-Brodeur A, Marcq G, Tholomier C, Fugaru I, Loutochin O, Anidjar M, et al. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer. J Urol. 2021;206:1177–83.
Yee CH, Chiu PKF, Teoh JYC, Ng CF, Chan CK, Hou SM. High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform. Adv Urol. 2021;2021:7157973.
Article PubMed PubMed Central Google Scholar
Ahn H, Hwang SI, Lee HJ, Kim SY, Cho JY, Lee H, et al. Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis. Prostate Int. 2023;11:59–68.
Khandwala YS, Morisetty S, Ghanouni P, Fan RE, Soerensen SJC, Rusu M, et al. Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation. Urol Oncol. 2022;40:489.e9–489.e17.
Pausch AM, Elsner C, Rupp NJ, Eberli D, Hötker AM. MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score. Eur J Radiol. 2024;175:111463.
Dellabella M, Branchi A, Di Rosa M, Pucci M, Gasparri L, Claudini R, et al. Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study. Prostate Cancer Prostatic Dis. 2021;24:1189–97.
Article CAS PubMed Google Scholar
Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, et al. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6:629–34.
Light A, Mayor N, Cullen E, Kirkham A, Padhani AR, Arya M, et al. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. Eur Urol. 2024;85:466–82.
Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol. 2016;69:41–9.
Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J, et al. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. Eur Urol Oncol 2021;4:868–76.
Comments (0)